Your AI-Trained Oncology Knowledge Connection!

Hans-Joachim Lück, MD

home / authors / hans-joachim-lück-md

Articles

UFT/Leucovorin Combined With Paclitaxel for Anthracycline-Pretreated Advanced Breast Cancer

Ursula Scholz, MD;Hans-Joachim Lück, MD;Ulrich Canzler, MD;Dagmar Robner, MD;Henning Kühnle, MD

October 1st 2000

Taxanes are the most active drugs in the treatment of metastatic breast and ovarian cancer. Weekly therapy with paclitaxel produces notable activity, with remarkably low toxicity.

UFT/Oral Calcium Folinate Plus Weekly Paclitaxel for Metastatic Breast Cancer

Hans-Joachim Lück, MD;Ursula Scholz, MD;H. Kühnle, MD;J. Dethling, MD

July 1st 1999

Paclitaxel (Taxol) is one of the most active drugs in the treatment of ovarian and breast cancers. Combination therapy with paclitaxel and 5-fluorouracil (5-FU) exhibits high activity in anthracycline-pretreated breast cancer,

Metastatic Breast Cancer: Experience with the Combination Paclitaxel Plus Epirubicin

Hans-Joachim Lück, MD

January 1st 1998

This study evaluated the safety and feasibility of the combination of paclitaxel (Taxol) and epirubicin, the 4¢-epimer of doxorubicin, in women with metastatic breast cancer. A total of 85 patients with histologically proven

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

Hans-Joachim Lück, MD;Andreas Du Bois, MD, PhD;Christoph Thomssen, MD, PhD;Björn Lisboa, MD, PhD;Michael Untch, MD, PhD;Günther Köhler, MD, PhD;Detlev Hecker, PhD;Klaus Diergarten, MD

April 1st 1997

Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in